I
IntegraGen
Leader in genome analysis and molecular diagnostics for oncology and autism
About IntegraGen
IntegraGen specializes in genome analysis and the development of molecular diagnostic tests, focusing on oncology and autism. The company operates in the healthcare and biotechnology sectors, serving clinical and research laboratories. IntegraGen's business model revolves around providing genomic services, including high throughput sequencing and bioinformatics, to help researchers and clinicians analyze genomic data. The company generates revenue through the commercialization of its molecular diagnostic tests and genomic services. By identifying novel genetic biomarkers, IntegraGen aims to translate molecular research into clinical practice, aiding in treatment decisions and advancing personalized medicine.
Source: Dealroom company dataAt a glance
- Founded
- 2000
- Headquarters
- Évry-Courcouronnes, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
CDC Enterprises
Eurazeo
BayTech Venture Capital
Bioam Gestion
DSM
Amundi
Innovation Capital
Generis Capital Partners- DVDSM Venturing
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IntegraGen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IntegraGen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.